Jia Jie Biomedical Co., Ltd. (TPEX:4109)
Taiwan
· Delayed Price · Currency is TWD 12.80
+0.05 (0.39%)
Mar 10, 2026, 12:21 PM CST
Jia Jie Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 3.26 | 211.37 | 144.15 | -5.47 | 5.34 | -31.93 | Upgrade
|
| Depreciation & Amortization | 17.08 | 15.8 | 14.89 | 16.87 | 13.44 | 15.66 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0.58 | 0.12 | -0.48 | 0.53 | -0.44 | Upgrade
|
| Loss (Gain) From Sale of Investments | 17.05 | -183.75 | -200.25 | - | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | -0.31 | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.01 | 0.05 | -0.28 | -0.71 | -0.3 | 0.01 | Upgrade
|
| Other Operating Activities | 7.82 | 10.71 | 1.56 | -1.36 | -0.08 | -3.93 | Upgrade
|
| Change in Accounts Receivable | -5.05 | -6.72 | -1.57 | -0.08 | -5.79 | 1.84 | Upgrade
|
| Change in Inventory | 9.32 | 0.41 | 1.96 | -5.84 | -5.75 | 38.88 | Upgrade
|
| Change in Accounts Payable | -1.84 | -4.87 | 1.09 | -1.37 | 1.39 | 3.71 | Upgrade
|
| Change in Unearned Revenue | -1.76 | -0.16 | 0.18 | -0.5 | 0.03 | -6.41 | Upgrade
|
| Change in Other Net Operating Assets | -15.13 | 0.92 | 33.99 | -9.84 | -4.44 | 9.7 | Upgrade
|
| Operating Cash Flow | 30.75 | 44.35 | -4.49 | -8.78 | 4.37 | 27.1 | Upgrade
|
| Operating Cash Flow Growth | 105.00% | - | - | - | -83.86% | 9.66% | Upgrade
|
| Capital Expenditures | -73.97 | -19.63 | -8.61 | -17.86 | -1.52 | -1.63 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.02 | 0.09 | 0.05 | 0.55 | 0.89 | 4.24 | Upgrade
|
| Cash Acquisitions | - | -41.3 | - | - | -7.52 | - | Upgrade
|
| Divestitures | - | - | - | - | - | 3.76 | Upgrade
|
| Investment in Securities | -166.51 | -68.07 | 12.97 | -14.95 | -158.42 | - | Upgrade
|
| Other Investing Activities | -1.75 | 0.77 | -1.86 | -2.75 | -6.48 | 0.96 | Upgrade
|
| Investing Cash Flow | -242.22 | -128.15 | 2.55 | -35.02 | -173.05 | 7.33 | Upgrade
|
| Short-Term Debt Issued | - | - | 242.45 | - | - | 83 | Upgrade
|
| Total Debt Issued | - | - | 242.45 | - | - | 83 | Upgrade
|
| Short-Term Debt Repaid | - | -237.45 | -5 | - | - | -143 | Upgrade
|
| Long-Term Debt Repaid | - | -2.7 | -2.88 | -3.73 | -2.49 | -6.25 | Upgrade
|
| Total Debt Repaid | -165.1 | -240.15 | -7.88 | -3.73 | -2.49 | -149.25 | Upgrade
|
| Net Debt Issued (Repaid) | -165.1 | -240.15 | 234.57 | -3.73 | -2.49 | -66.25 | Upgrade
|
| Issuance of Common Stock | 360 | 130.73 | - | - | - | 272 | Upgrade
|
| Common Dividends Paid | - | -49.37 | - | - | - | - | Upgrade
|
| Other Financing Activities | 164.41 | 0.02 | - | - | 0 | - | Upgrade
|
| Financing Cash Flow | 359.31 | -158.77 | 234.57 | -3.73 | -2.49 | 205.75 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.08 | 1.09 | -3.74 | 0.78 | -0.73 | -0.39 | Upgrade
|
| Net Cash Flow | 147.91 | -241.48 | 228.89 | -46.74 | -171.89 | 239.79 | Upgrade
|
| Free Cash Flow | -43.23 | 24.72 | -13.1 | -26.64 | 2.85 | 25.47 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -88.79% | 17.59% | Upgrade
|
| Free Cash Flow Margin | -8.97% | 4.60% | -3.94% | -8.38% | 1.18% | 9.42% | Upgrade
|
| Free Cash Flow Per Share | -0.39 | 0.25 | -0.15 | -0.30 | 0.03 | 0.37 | Upgrade
|
| Cash Interest Paid | 0.09 | 0.64 | 0.35 | 0.11 | 0.06 | 0.71 | Upgrade
|
| Cash Income Tax Paid | 10.96 | 3.41 | 0.84 | 2.11 | -0 | -5.23 | Upgrade
|
| Levered Free Cash Flow | 2.32 | 0.17 | 2.6 | -27.76 | -4.52 | 34.49 | Upgrade
|
| Unlevered Free Cash Flow | 2.45 | 0.57 | 2.82 | -27.69 | -4.49 | 34.94 | Upgrade
|
| Change in Working Capital | -14.46 | -10.42 | 35.64 | -17.63 | -14.56 | 47.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.